2ccPA sodium
2ccPA (2ccPA18:1) sodium is a chemically stable cyclic phosphatidic acid derivative and antifibrotic inhibitor-inducer. 2ccPA sodium increases intracellular cAMP levels in skin fibroblasts, downregulates the expression of extracellular matrix (ECM) components, and promotes the production of antifibrotic factors HGF and PGE2. 2ccPA sodium ameliorates Bleomycin hydrochloride (HY-17565A)-induced skin fibrosis in mice and can be used for research on systemic sclerosis (SSc) and other fibrotic disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 927880-40-8
- Formule: C22H40NaO5P
- Masse moléculaire:438.51
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
|
Collagen I |
In Vitro
2ccPA (2ccPA18:1) (1-10 μM; 48-72 h) sodium does not reduce the viability of SSc skin fibroblasts or healthy skin fibroblasts, while 2ccPA (100 μM; 48-72 h) sodium significantly reduces viability of SSc skin fibroblasts at these time points[1].
2ccPA (10 μM; 48 h) sodium inhibits the upregulation of profibrotic mRNA markers (COL1A1, COL1A2, CTGF, ACTA2) in TGF-β1-stimulated healthy skin fibroblasts[1].
2ccPA (10 μM; 72 h) sodium reduces the protein expression of profibrotic markers (type I collagen, CCN2, αSMA) in TGF-β1-stimulated healthy skin fibroblasts[1].
2ccPA (1-10 μM; 48 h) sodium dose-dependently reduces profibrotic mRNA marker (COL1A1, COL1A2, CTGF, ACTA2) expression in SSc skin fibroblasts, and 2ccPA (10 μM; 6-48 h) sodium maintains this inhibitory effect on additional markers (FN, TGF-β1) for up to 48 h[1].
2ccPA (10 μM; 48 h) sodium reduces the protein expression of type I collagen and CCN2 in SSc skin fibroblasts, but 2ccPA (10 μM; 72 h) sodium does not significantly decrease procollagen type I levels in culture supernatant[1].
2ccPA (10 μM; 24 h) sodium significantly elevates the production of antifibrotic factors HGF and PGE2 in SSc skin fibroblasts[1].
2ccPA (1-10 μM; 30 min) sodium dose-dependently increases intracellular cAMP levels in SSc skin fibroblasts[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:systemic sclerosis (SSc) skin fibroblasts, healthy skin fibroblasts
-
Concentration:1, 10, 100 μM
-
Incubation Time:48 h, 72 h
-
Result:Did not affect the viability of SSc skin fibroblasts and healthy skin fibroblasts at 1-10 μM for 48 or 72 h.
Significantly reduced SSc skin fibroblast viability at 100 μM for 48 and 72 h.
Showed a similar viability profile in healthy skin fibroblasts.
-
Cell Line:healthy skin fibroblasts treated with TGF-β1
-
Concentration:10 μM
-
Incubation Time:48 h
-
Result:Downregulated the mRNA expression levels of extracellular matrix (ECM) molecules COL1A1, COL1A2, CTGF, and ACTA2 in TGF-β1-stimulated healthy skin fibroblasts.
-
Cell Line:healthy skin fibroblasts treated with TGF-β1
-
Concentration:10 μM
-
Incubation Time:72 h
-
Result:Decreased the protein expression levels of type I collagen, CCN2, and αSMA in TGF-β1-stimulated healthy skin fibroblasts.
-
Cell Line:systemic sclerosis (SSc) skin fibroblasts
-
Concentration:1, 10 μM
-
Incubation Time:6 h, 24 h, 48 h
-
Result:Downregulated the mRNA expression levels of COL1A1, COL1A2, CTGF, and ACTA2 in SSc skin fibroblasts in a dose-dependent manner after 48 h.
Significantly reduced mRNA expression of COL1A1, COL1A2, CTGF, ACTA2, FN, and TGF-β1 compared to untreated cells after 6, 24, or 48 h, with the antifibrotic effect detectable up to 48 h.
-
Cell Line:systemic sclerosis (SSc) skin fibroblasts
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Significantly increased the levels of HGF and PGE2 in the culture medium of SSc skin fibroblasts compared to untreated cells.
In Vivo
2ccPA (1.6 mg/kg; i.p.; once daily; 0-5 weeks) nearly completely suppresses acute peak demyelination, increases the number of myelinated axons, and suppresses Iba1, GFAP, NLRP3, P2X7R, IL-1β upregulation and microglial activation in C57BL/6J mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (6-week-old female; bleomycin-induced skin fibrosis)[1]
-
Dosage:1 mg/kg; 10 mg/kg
-
Administration:i.p.; once daily for 4 weeks
-
Result:Reduced skin thickness and collagen content by 22.5% (not significant) at 1 mg/kg/day compared with Bleomycin-only controls.
Reduced skin thickness, reduced collagen content by 32%, and reduced αSMA-positive myofibroblast count by 45% at 10 mg/kg/day compared with Bleomycin-only controls.
Showed no side effects or significant body weight reduction.
-
Animal Model:Male C57BL/6J mice[2]
-
Dosage:1.6 mg/kg
-
Administration:i.p.; once daily for 5 weeks
-
Result:Nearly completely suppressed acute peak demyelination and reduced neuroinflammation.
Chemical Information
-
CAS No. 927880-40-8
-
Masse moléculaire 438.51
-
Formule C22H40NaO5P
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OCC1COP(C1)(O[Na])=O)=O
-
Synonyms
2ccPA18:1 sodium
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Higuchi T, et al. Antifibrotic effects of 2-carba cyclic phosphatidic acid (2ccPA) in systemic sclerosis: contribution to the novel treatment. Arthritis Res Ther. 2019 Apr 18;21(1):103. [Content Brief]
[2]. Yamamoto S, et al. Correction to: Protective and therapeutic role of 2-carbacyclic phosphatidic acid in demyelinating disease. J Neuroinflammation. 2018 Mar 5;15(1):67. [Content Brief]
[3]. Hashimoto K, et al. 2-carba cyclic phosphatidic acid suppresses inflammation via regulation of microglial polarisation in the stab-wounded mouse cerebral cortex. Sci Rep. 2018 Jun 26;8(1):9715. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
2ccPA sodium Related Classifications
HY-160823 Related Classifications
Powered by Bioz